Report

Global Hemato Oncology Testing Market Size study & Forecast, by Product & Services, Cancer (Leukemia, Non-Hodgkin's Lymphoma), Technology, End-User and Regional Analysis, 2022-2029

  • Publish Date: Feb,2023
  • Report ID: 3-2-1764
  • Page : 200
  • Report Type : PDF (Email)
Table of Contents
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Hemato Oncology Testing Market, by Region, 2019-2029 (USD Billion)
1.2.2. Hemato Oncology Testing Market, by Product & Service, 2019-2029 (USD Billion)
1.2.3. Hemato Oncology Testing Market, by Cancer Type, 2019-2029 (USD Billion)
1.2.4. Hemato Oncology Testing Market, by Technology, 2019-2029 (USD Billion)
1.2.5. Hemato Oncology Testing Market, by End-User, 2019-2029 (USD Billion)
1.2.6.
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Hemato Oncology Testing Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Hemato Oncology Testing Market Dynamics
3.1. Hemato Oncology Testing Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Rising incidences of hematologic cancer
3.1.1.2. Increasing demand for personalized therapy
3.1.2. Market Challenges
3.1.2.1. Unfavorable Reimbursement Scenario
3.1.3. Market Opportunities
3.1.3.1. Rising advanced molecular techniques for hemato-oncology diagnostics
3.1.3.2. Increasing drug-diagnostics co-development
Chapter 4. Global Hemato Oncology Testing Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Investment Adoption Model
4.5. Analyst Recommendation & Conclusion
4.6. Top investment opportunity
4.7. Top winning strategies
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre-COVID-19D-19 and post-COVID-19 Market scenario
Chapter 6. Global Hemato Oncology Testing Market, by Product & Service,
6.1. Market Snapshot
6.2. Global Hemato Oncology Testing Market by Product & Service, Performance - Potential Analysis
6.3. Global Hemato Oncology Testing Market Estimates & Forecasts by Product & Service, 2019-2029 (USD Billion)
6.4. Hemato Oncology Testing Market, Sub-Segment Analysis
6.4.1. Assay Kits,
6.4.2. Services
Chapter 7. Global Hemato Oncology Testing Market, by Cancer Type
7.1. Market Snapshot
7.2. Global Hemato Oncology Testing Market by Cancer Type, Performance - Potential Analysis
7.3. Global Hemato Oncology Testing Market Estimates & Forecasts by Cancer Type 2019-2029 (USD Billion)
7.4. Hemato Oncology Testing Market, Sub Segment Analysis
7.4.1. Leukemia
7.4.2. Non-Hodgkin's Lymphoma
Chapter 8. Global Hemato Oncology Testing Market, by Technology,
8.1. Market Snapshot
8.2. Global Hemato Oncology Testing Market by Technology, Performance - Potential Analysis
8.3. Global Hemato Oncology Testing Market Estimates & Forecasts by Technology, 2019-2029 (USD Billion)
8.4. Hemato Oncology Testing Market, Sub Segment Analysis
8.4.1. PCR, Polymerase chain reaction
8.4.2. NGS, Next-generation sequencing (NGS)
8.4.3. IHC Immunohistochemistry (IHC)
Chapter 9. Global Hemato Oncology Testing Market, by End-User
9.1. Market Snapshot
9.2. Global Hemato Oncology Testing Market by End-User, Performance - Potential Analysis
9.3. Global Hemato Oncology Testing Market Estimates & Forecasts by End-User 2019-2029 (USD Billion)
9.4. Hemato Oncology Testing Market, Sub Segment Analysis
9.4.1. Clinical Laboratories,
9.4.2. Hospitals
Chapter 10. Global Hemato Oncology Testing Market, Regional Analysis
10.1. Hemato Oncology Testing Market, Regional Market Snapshot
10.2. North America Hemato Oncology Testing Market
10.2.1. U.S. Hemato Oncology Testing Market
10.2.1.1. Product & Services breakdown estimates & forecasts, 2019-2029
10.2.1.2. Cancer Type breakdown estimates & forecasts, 2019-2029
10.2.1.3. Technology breakdown estimates & forecasts, 2019-2029
10.2.1.4. End-User breakdown estimates & forecasts, 2019-2029
10.2.2. Canada Hemato Oncology Testing Market
10.3. Europe Hemato Oncology Testing Market Snapshot
10.3.1. U.K. Hemato Oncology Testing Market
10.3.2. Germany Hemato Oncology Testing Market
10.3.3. France Hemato Oncology Testing Market
10.3.4. Spain Hemato Oncology Testing Market
10.3.5. Italy Hemato Oncology Testing Market
10.3.6. Rest of Europe Hemato Oncology Testing Market
10.4. Asia-Pacific Hemato Oncology Testing Market Snapshot
10.4.1. China Hemato Oncology Testing Market
10.4.2. India Hemato Oncology Testing Market
10.4.3. Japan Hemato Oncology Testing Market
10.4.4. Australia Hemato Oncology Testing Market
10.4.5. South Korea Hemato Oncology Testing Market
10.4.6. Rest of Asia Pacific Hemato Oncology Testing Market
10.5. Latin America Hemato Oncology Testing Market Snapshot
10.5.1. Brazil Hemato Oncology Testing Market
10.5.2. Mexico Hemato Oncology Testing Market
10.6. Rest of The World Hemato Oncology Testing Market
Chapter 11. Competitive Intelligence
11.1. Top Market Strategies
11.2. Company Profiles
11.2.1. F. Hoffmann-La Roche Ltd
11.2.1.1. Key Information
11.2.1.2. Overview
11.2.1.3. Financial (Subject to Data Availability)
11.2.1.4. Product Summary
11.2.1.5. Recent Developments
11.2.2. Abbott
11.2.3. Invitae Corporation (Archerdx, Inc)
11.2.4. QIAGEN
11.2.5. Thermo Fisher Scientific Inc.
11.2.6. Illumina Inc.
11.2.7. Bio-Rad Laboratories, Inc.-
11.2.8. Molecularmd (Subsidiary of Icon PLC)
11.2.9. Asuragen, Inc.
11.2.10. Arup Laboratories Inc.
Chapter 12. Research Process
12.1. Research Process
12.1.1. Data Mining
12.1.2. Analysis
12.1.3. Market Estimation
12.1.4. Validation
12.1.5. Publishing
12.2. Research Attributes
12.3. Research Assumption